Drug extends life of younger women with advanced breast cancer
The study was conducted among 672 women under the age of 59 who received a drug called ribociclib, in combination with a common form of hormone therapy. Seventy percent of the women who took the combination therapy were alive after 42 months according to the findings, compared to 46% for women who were treated with… Read More »